Do NAD+ blood tests mean anything?

Reviewed 18 sourcesPublished by PepVault

What a finger-prick NAD+ test measures, whether NAD+ falls with age in human studies, and what one number can and cannot tell you about your body.

A woman in a yellow long-sleeve top tying a white shoe on sunny porch steps, fruit and a glass of water beside her
Last reviewed
Sources
18
Questions
7
Compounds
3

The short answer

Partly. A finger-prick NAD+ test measures NAD+ in whole blood, most of it inside red blood cells. It shows well whether an NMN or NR supplement is raising that level, which often doubles in trials. It cannot tell your biological age or what your muscle and brain hold: a 2026 study of seven cohorts found whole-blood NAD+ did not change with age.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Mixed. Human tissue studies (skin, brain, muscle, liver) find lower NAD+ with age; blood studies conflict, and the largest, across seven cohorts in 2026, found no change with age. Precursor trials reliably raise blood NAD+, with small and inconsistent clinical effects.

A woman in a yellow long-sleeve top tying a white shoe on sunny porch steps, fruit and a glass of water beside her

What does an NAD+ blood test actually measure?

NAD+ (nicotinamide adenine dinucleotide) is the molecule every cell uses to turn food into energy, and the fuel burned by the sirtuins and by PARP, a DNA-repair enzyme4. Almost all of it sits inside cells2. So the first question about any NAD+ test is which part of the blood it read, because the answer changes the number a thousandfold or more.

What the test readsWhat it holdsHealthy adults in studiesKind of test
Whole bloodMostly the NAD+ inside red blood cellsAbout 20 to 45 µM (micromoles per litre) on average3810Finger-prick tests (dried spot or sensor) and research mass spectrometry
Plasma or serumThe small amount outside cellsNanomoles per litre, often too low to measure29Standard draws, some colorimetric kits
White blood cells (PBMCs)NAD+ in immune cells, per mg of proteinReported as pmol per mg protein9Research labs only
A blood tube split into plasma and the cell layer, with NAD+ drawn as dots nearly all in the cell layer: whole blood about 20 to 45 µM, plasma in nanomoles per litre
Almost all the NAD+ in blood is inside the cells, so a whole-blood test and a plasma test read numbers a thousand times apart.

The consumer tests sold as "intracellular NAD" are whole-blood tests: a few drops from a finger dry on a card and go to a lab. In a 2023 validation of a finger-prick sensor test, a 5 µL drop matched a vein sample within 15% (Pearson's r = 0.987 in 13 volunteers)3. That is a real measurement. The catch is in what it is a measurement of, which the rest of this guide takes in turn.

Units are the trap. One 60-day NMN trial used a serum kit that reads NAD+ and its reduced form NADH together; its participants started at a median of 7.21 nM (nanomoles per litre)1118. Whole-blood studies of adults report about 21,000 to 32,000 nM810. Neither number is wrong. They measure different things, and a result can be compared only with a result from the same kind of test.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault's Bloodwork section you can add NAD+ as a custom marker with its own unit, and each new result joins that marker's trend line, so you read every retest against your own baseline.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does NAD+ fall with age?

In tissue, the human studies point the same way. In skin taken during surgery from 49 people aged newborn to 77, NAD+ fell steadily with age (r = -0.706 in men, -0.537 in women)4. A magnetic-resonance scan that reads NAD+ in the living brain found lower NAD+ in older healthy volunteers5. Muscle biopsies showed lower NAD+ in older adults, lowest in the physically impaired, while exercise-trained older adults had levels close to the young6. Liver samples from older patients held less NAD+ as well7.

In blood, the studies disagree, and the largest and newest says no.

StudySampleWhoAge finding
Clement 20192Plasma, LC-MS29 healthy adults, 20 to 87Lower NAD+ in the over-60s than the 20-to-40s
Wang 20233Whole blood, finger-prick sensor142 adultsMen fell from 44.2 to 25.9 µM, women from 32.7 to 24.8 µM, under 50 against 50 to 85
Trętowicz 20261Whole blood, validated high-resolution LC-MSSeven independent cohortsRemarkably stable with age and across lifestyle interventions

The 2026 study, from the Amsterdam UMC group, built its method to account for real-world variation between runs and samples, and its authors conclude that their results "challenge the utility of blood NAD+ levels as a biomarker of ageing or lifestyle factors"1. The same method did pick up a rise after nicotinamide riboside (NR), so it was able to see a change when one was there1. On age, all three are observational studies: they compare people of different ages at one point in time, not the same people as they age.

Why do the blood studies disagree?

Three things move the number besides the person. The first is handling. NAD+ is unstable in blood10: in liquid whole blood kept in a fridge, the measured NAD+ read 124% of the first-day value after 2 days, 135% after a week and 64% after a month10. Drying the drop on a treated card held it at 85% or more for 2 weeks in the fridge and a week at room temperature10, which is what the dried-card kits rely on.

The second is the method. Mass spectrometry (LC-MS) separates NAD+ from its look-alikes and counts it directly. Enzyme and colour-change kits are cheaper, and some read NAD+ and NADH as one total11. The third is size: an age effect found in 29 people2 can vanish across several larger cohorts1.

Does a blood number show what your muscles hold?

Not reliably, and one trial shows it in the same people. Twelve older men took 1 g of NR a day for 21 days, against placebo, in a randomized, double-blind crossover trial (each man had both periods)8. Their whole-blood NAD+ was more than double on NR: 47.75 µM against 20.90 µM on placebo. In their thigh muscle, NAD+ itself did not move: 210 against 197 pmol per mg on placebo (p = 0.22)8. The muscle did show that NR arrived, with twice the NAAD, a by-product of making new NAD+8.

So a blood result tells you about blood. It shows the supplement was absorbed; it does not show that the tissue you care about filled up.

Paired bars from Elhassan 2019: whole-blood NAD+ 20.9 µM on placebo against 47.75 µM on NR; thigh-muscle NAD+ 197 against 210 pmol per mg
The same 12 men: NR more than doubled blood NAD+, while the NAD+ in their thigh muscle stayed level.

What happened in trials when blood NAD+ went up?

Raising the blood number is the easy part, and the trials did it again and again. What came with it was smaller and less consistent:

TrialWho and whatBlood NAD+What else changed
Airhart 2017138 healthy adults, NR rising to 1,000 mg twice daily, open-labelWhole blood up 100%A pharmacokinetic study; no outcome measured
Martens 2018930 adults 55 to 79, NR 500 mg twice daily, 6 weeksPBMC NAD+ up about 60%Blood pressure and artery stiffness flagged for bigger trials only
Igarashi 202214Older men, NMN 250 mg a day, 6 or 12 weeksWhole blood upNominal gains in gait speed and grip; body composition unchanged
Yi 20231180 adults 40 to 65, NMN 300 to 900 mg a day, 60 daysSerum NAD up in all dosesLonger 6-minute walk; insulin resistance unchanged
Christen 20261765 healthy adults, NR, NMN or nicotinamide, 14 daysNR and NMN raised it about equally; nicotinamide did notA comparison of the boosters

Against them, a 12-week trial of 2,000 mg NR a day in 40 men with obesity found no change in insulin sensitivity, glucose handling or body composition15. The clearest positive result, higher muscle insulin sensitivity with NMN in women past menopause with prediabetes, came from a clamp test and muscle biopsies, not from a blood NAD+ reading16. The doses are the trials' own, told as the studies ran them, not a dosing plan. The precursors themselves are compared on PepVault's NAD+ vs NMN page, pepvault.app/peptides/compare/nad-vs-nmn.

Every number in this guide comes from people. The animal work, such as NR reversing fatty liver in NAD+-deficient mice7, is a separate body of evidence and does not stand in for these results.

So what can one NAD+ number tell you?

It can tell you two useful things. First, whether a precursor is reaching your blood. Responses vary more than most people expect: in the 60-day NMN trial, the spread of the rise inside each dose group (its coefficient of variation) ran from 29% to 113%12, and in the 6-week NR trial the people who started lowest rose the most9. Second, your own baseline is steady. Six people tested twice a week for 100 days stayed mostly flat; sleep loss and menstruation did not shift it, and the one jump came from a participant who started NMN3.

It cannot tell you your biological age1, your muscle or brain NAD+8, or whether you are healthier. And the "optimal" bands printed on consumer reports are the test makers' own: we found no published study that ties a band to a health outcome.

Commonly reported: a first finger-prick result graded low or suboptimal, then a much higher number on the retest after a few weeks of NMN or NR.

  1. Take your first test before you start a precursor, so you have your own baseline to compare against.
  2. Use the same kind of test each time (the same sample type and, ideally, the same lab), because whole blood, serum and plasma differ a thousandfold.
  3. Test at a similar time of day and before that day's dose: in one study a single NMN dose raised finger-prick NAD+ within 60 minutes3.
  4. Follow the kit's drying and posting instructions exactly, since NAD+ in a liquid sample drifts within days10.
  5. Retest after several weeks; the trials above read their results at 2 to 12 weeks.
  6. Read the change against your own baseline, not against the report's colour band.

In PepVault's Bloodwork section you can add NAD+ as a custom marker with its own unit, and each new result joins that marker's trend line, so you read every retest against your own baseline. Log it in PepVault

Where to read more

  • The library pages: pepvault.app/peptides/nad, /peptides/nmn and /peptides/nicotinamide-riboside, and the longevity hub at pepvault.app/longevity.
  • Study pages for the trials above: pepvault.app/research/nad-martens-2018, /research/nad-christen-2026, /research/nmn-igarashi-2022, /research/nmn-yi-2023 and /research/nad-yoshino-2021.
  • Observational study, crossover trial, placebo and randomized controlled trial are explained at pepvault.app/glossary/observational-study, /glossary/crossover-trial, /glossary/placebo and /glossary/randomized-controlled-trial.

Track it in the app

Sources

  1. Trętowicz MM et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8:1282-1290. PubMed 42135539
  2. Clement J et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Res. 2019;22:121-130. PubMed 30124109
  3. Wang P et al. Fingerstick blood assay maps real-world NAD+ disparity across gender and age. Aging Cell. 2023;22:e13965. PubMed 37641521
  4. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7:e42357. PubMed 22848760
  5. Zhu XH et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015;112:2876-2881. PubMed 25730862
  6. Janssens GE et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nat Aging. 2022;2:254-263. PubMed 37118369
  7. Zhou CC et al. Hepatic NAD+ deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173:2352-2368. PubMed 27174364
  8. Elhassan YS et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28:1717-1728. PubMed 31412242
  9. Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PubMed 29599478
  10. Matsuyama R et al. Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling. Anal Bioanal Chem. 2023;415:775-785. PubMed 36504284
  11. Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45:29-43. PubMed 36482258
  12. Kuerec AH et al. Towards personalized nicotinamide mononucleotide (NMN) supplementation: nicotinamide adenine dinucleotide (NAD) concentration. Mech Ageing Dev. 2024;218:111917. PubMed 38430946
  13. Airhart SE et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12:e0186459. PubMed 29211728
  14. Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8:5. PubMed 35927255
  15. Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108:343-353. PubMed 29992272
  16. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-1229. PubMed 33888596
  17. Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8:62-73. PubMed 41540253
  18. Kuerec AH et al. Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial. GeroScience. 2026;48:3305-3313. PubMed 41162813

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo